0 5 IL-10 IL-10 NNP 6 14 inhibits inhibit VBZ 15 22 nuclear nuclear JJ 23 35 factor-kappa factor-kappa NN 36 41 B/Rel B/Rel NNP 42 49 nuclear nuclear JJ 50 58 activity activity NN 59 61 in in IN 62 76 CD3-stimulated cd3-stimulated JJ 77 82 human human JJ 83 93 peripheral peripheral JJ 94 95 T t NN 96 107 lymphocytes lymphocyte NNS 107 108 . . . 110 115 IL-10 IL-10 NNP 116 124 markedly markedly RB 125 132 reduces reduce VBZ 133 140 nuclear nuclear JJ 141 147 factor factor NN 148 149 ( ( ( 149 158 NF)-kappa NF)-kappa NNP 159 164 B/Rel B/Rel NNP 165 172 nuclear nuclear JJ 173 181 activity activity NN 182 189 induced induce VBN 190 192 in in IN 193 197 PBMC PBMC NNP 198 200 by by IN 201 212 stimulation stimulation NN 213 217 with with IN 218 221 the the DT 222 230 anti-CD3 anti-cd3 JJ 231 234 mAb mab NN 235 239 OKT3 okt3 NN 239 240 . . . 241 244 The the DT 245 255 inhibition inhibition NN 256 258 is be VBZ 259 266 exerted exert VBN 267 279 specifically specifically RB 280 282 on on IN 283 286 the the DT 287 295 NF-kappa NF-kappa NNP 296 301 B/Rel B/Rel NNP 302 312 activation activation NN 313 320 induced induce VBN 321 323 by by IN 324 327 mAb mab NN 328 332 OKT3 okt3 NN 332 333 , , , 334 337 and and CC 338 341 not not RB 342 346 that that DT 347 355 produced produce VBN 356 358 by by IN 359 362 PMA PMA NNP 362 363 . . . 364 366 As as IN 367 373 judged judge VBN 374 376 by by IN 377 390 supershifting supershifte VBG 391 394 the the DT 395 406 DNA-protein dna-protein JJ 407 416 complexes complex NNS 417 421 with with IN 422 425 Abs ab NNS 426 437 recognizing recognize VBG 438 446 specific specific JJ 447 457 components component NNS 458 460 of of IN 461 464 the the DT 465 473 NF-kappa NF-kappa NNP 474 479 B/Rel B/Rel NNP 480 487 protein protein NN 488 494 family family NN 494 495 , , , 496 499 the the DT 500 507 p50/p65 p50/p65 NN 508 509 ( ( ( 509 512 Rel Rel NNP 513 514 A A NNP 514 515 ) ) ) 516 529 heterodimeric heterodimeric JJ 530 534 form form NN 535 537 of of IN 538 546 NF-kappa NF-kappa NNP 547 548 B B NNP 549 551 is be VBZ 552 561 primarily primarily RB 562 570 affected affect VBN 570 571 . . . 572 575 The the DT 576 583 maximal maximal JJ 584 590 effect effect NN 591 593 is be VBZ 594 602 observed observe VBN 603 605 at at IN 606 609 the the DT 610 615 IL-10 il-10 NN 616 629 concentration concentration NN 630 632 of of IN 633 635 20 20 CD 636 641 U/ml. U/ml. NNP 642 647 IL-10 IL-10 NNP 648 658 inhibitory inhibitory JJ 659 667 activity activity NN 668 670 is be VBZ 671 678 exerted exert VBN 679 681 on on IN 682 683 T t NN 684 695 lymphocytes lymphocyte NNS 696 699 and and CC 700 702 is be VBZ 703 711 mediated mediate VBN 712 714 by by IN 715 724 monocytes monocyte NNS 724 725 . . . 726 732 Indeed indeed RB 732 733 , , , 734 743 monocytes monocyte NNS 744 754 pretreated pretreate VBN 755 759 with with IN 760 765 IL-10 IL-10 NNP 766 769 are be VBP 770 774 able able JJ 775 777 so so RB 778 785 inhibit inhibit VB 786 794 NF-kappa NF-kappa NNP 795 796 B B NNP 797 804 nuclear nuclear JJ 805 813 activity activity NN 814 816 in in IN 817 825 purified purify VBN 826 827 T t NN 828 839 lymphocytes lymphocyte NNS 840 850 stimulated stimulate VBN 851 855 with with IN 856 860 OKT3 OKT3 NNP 860 861 . . . 862 869 Soluble soluble JJ 870 877 factors factor NNS 878 880 do do VBP 881 884 not not RB 885 891 appear appear VB 892 894 to to TO 895 897 be be VB 898 906 involved involve VBN 907 909 in in IN 910 913 the the DT 914 923 mechanism mechanism NN 924 926 of of IN 927 937 inhibition inhibition NN 937 938 . . . 939 941 On on IN 942 945 the the DT 946 951 other other JJ 952 956 hand hand NN 956 957 , , , 958 961 the the DT 962 975 up-regulation up-regulation NN 976 978 of of IN 979 983 CD80 CD80 NNP 984 986 Ag Ag NNP 986 987 , , , 988 993 found find VBN 994 996 on on IN 997 1006 monocytes monocyte NNS 1007 1015 obtained obtain VBN 1016 1020 from from IN 1021 1025 PBMC PBMC NNP 1026 1035 incubated incubate VBN 1036 1040 with with IN 1041 1045 OKT3 OKT3 NNP 1045 1046 , , , 1047 1049 is be VBZ 1050 1053 not not RB 1054 1062 detected detect VBN 1063 1068 after after IN 1069 1077 addition addition NN 1078 1080 of of IN 1081 1086 IL-10 IL-10 NNP 1086 1087 , , , 1088 1091 and and CC 1092 1095 the the DT 1096 1105 anti-CD28 anti-cd28 JJ 1106 1109 mAb mab NN 1110 1120 CLB-CD28/1 clb-cd28/1 NN 1121 1129 restores restore VBZ 1130 1133 the the DT 1134 1142 NF-kappa NF-kappa NNP 1143 1148 B/Rel B/Rel NNP 1149 1156 nuclear nuclear JJ 1157 1165 activity activity NN 1166 1168 in in IN 1169 1184 IL-10-inhibited il-10-inhibited JJ 1185 1196 lymphocytes lymphocyte NNS 1196 1197 . . . 1198 1207 Therefore therefore RB 1207 1208 , , , 1209 1212 the the DT 1213 1221 NF-kappa NF-kappa NNP 1222 1227 B/Rel B/Rel NNP 1228 1238 inhibition inhibition NN 1239 1244 might might MD 1245 1247 be be VB 1248 1256 ascribed ascribe VBN 1257 1259 to to TO 1260 1261 a a DT 1262 1266 lack lack NN 1267 1269 of of IN 1270 1281 cooperation cooperation NN 1282 1289 between between IN 1290 1299 accessory accessory JJ 1300 1305 cells cell NNS 1306 1309 and and CC 1310 1311 T t NN 1312 1323 lymphocytes lymphocyte NNS 1323 1324 , , , 1325 1334 resulting result VBG 1335 1339 from from IN 1340 1355 down-regulation down-regulation NN 1356 1358 of of IN 1359 1360 a a DT 1361 1374 costimulatory costimulatory JJ 1375 1383 molecule molecule NN 1383 1384 , , , 1385 1389 such such JJ 1390 1392 as as IN 1393 1397 CD80 CD80 NNP 1397 1398 , , , 1399 1407 produced produce VBN 1408 1410 by by IN 1411 1416 IL-10 il-10 NN 1417 1419 on on IN 1420 1429 activated activate VBN 1430 1439 monocytes monocyte NNS 1439 1440 . . . 1441 1444 Our our PRP$ 1445 1452 results result NNS 1453 1464 demonstrate demonstrate VBP 1465 1469 that that IN 1470 1475 IL-10 il-10 NN 1476 1479 can can MD 1480 1487 inhibit inhibit VB 1488 1491 the the DT 1492 1501 induction induction NN 1502 1504 of of IN 1505 1513 NF-kappa NF-kappa NNP 1514 1519 B/Rel B/Rel NNP 1520 1527 nuclear nuclear JJ 1528 1536 activity activity NN 1537 1539 in in IN 1540 1554 CD3-stimulated cd3-stimulated JJ 1555 1556 T t NN 1557 1568 lymphocytes lymphocyte NNS 1568 1569 . . . 1570 1575 Since since IN 1576 1589 inappropriate inappropriate JJ 1590 1600 activation activation NN 1601 1603 of of IN 1604 1609 kappa kappa NN 1610 1618 B-driven b-driven JJ 1619 1624 genes gene NNS 1625 1628 has have VBZ 1629 1630 a a DT 1631 1647 physiopathologic physiopathologic JJ 1648 1652 role role NN 1653 1655 in in IN 1656 1657 a a DT 1658 1664 number number NN 1665 1667 of of IN 1668 1676 diseases disease NNS 1676 1677 , , , 1678 1682 such such JJ 1683 1685 as as IN 1686 1689 HIV HIV NNP 1690 1699 infection infection NN 1699 1700 , , , 1701 1704 our our PRP$ 1705 1713 findings finding NNS 1714 1721 support support VBP 1722 1725 the the DT 1726 1737 possibility possibility NN 1738 1740 of of IN 1741 1746 using use VBG 1747 1751 this this DT 1752 1760 cytokine cytokine NN 1761 1763 to to TO 1764 1772 suppress suppress VB 1773 1775 an an DT 1776 1787 undesirable undesirable JJ 1788 1798 activation activation NN 1799 1801 of of IN 1802 1807 these these DT 1808 1821 transcription transcription NN 1822 1829 factors factor NNS 1829 1830 . . .